Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 3/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.44 |
| ▸ | HCAR2 | Q8TDS4 | 11/20 | 0.42 |
| ▸ | MAPT | P10636 | 2/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.36 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.36 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.33 |
| ▸ | RECQL | P46063 | 1/20 | 0.33 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.33 |
| ▸ | GAA | P10253 | 1/20 | 0.32 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.31 |
| ▸ | NFE2L2 | Q16236 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28074131 | 0.84 | TSHR (0.59) | TSHRALDH1A1MAPTHSD17B10 | |
| SCHEMBL182314 | 0.84 | HCAR2 (0.57) | TSHRALDH1A1HCAR2MAPTGAA | |
| SCHEMBL182315 | 0.84 | HCAR2 (0.57) | TSHRALDH1A1HCAR2MAPTGAA | |
| SCHEMBL2808163 | 0.84 | HCAR2 (0.57) | TSHRALDH1A1HCAR2MAPTGAA | |
| Ammonia Solution, Strong SCHEMBL28647186 | 0.82 | HCAR2 (0.55) | TSHRALDH1A1HCAR2MAPTGAA | |
| SCHEMBL195021 | 0.82 | TSHR (0.47) | TSHRALDH1A1HCAR2MAPTKDM4E | |
| SCHEMBL3914403 | 0.82 | TSHR (0.47) | TSHRALDH1A1HCAR2MAPTKDM4E | |
| SCHEMBL11796011 | 0.82 | TSHR (0.47) | TSHRALDH1A1HCAR2MAPTKDM4E | |
| Ethyl Fumarate SCHEMBL1066994 | 0.81 | HCAR2 (0.67) | TSHRALDH1A1HCAR2MAPTKDM4E | |
| SCHEMBL28568205 | 0.81 | ALDH1A1 (0.46) | TSHRALDH1A1HCAR2MAPTKDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080286377-A1 | ANTI-RESORPTIVE BONE CEMENTS AND ALLOGENEIC, AUTOGRAFIC, AND XENOGRAFIC BONE GRAFTS | SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH | 2008-11-20 | — | — | US | disclosed |
| EP-1150684-A4 | ANTI-RESORPTIVE BONE CEMENTS AND ALLOGENEIC, AUTOGRAFIC, AND XENOGRAFIC BONE GRAFTS | SLOAN KETTERING INSTITUTEFOR C (US) | 2005-06-15 | — | — | EP | disclosed |
| WO-2000047214-A9 | ANTI-RESORPTIVE BONE CEMENTS AND ALLOGENEIC, AUTOGRAFIC, AND XENOGRAFIC BONE GRAFTS | SLOAN KETTERING INST CANCER (US) | 2002-04-11 | — | — | WO | disclosed |
| EP-1150684-A1 | ANTI-RESORPTIVE BONE CEMENTS AND ALLOGENEIC, AUTOGRAFIC, AND XENOGRAFIC BONE GRAFTS | Sloan-Kettering Institute For Cancer Research (US) | 2001-11-07 | — | — | EP | disclosed |
| WO-2000047214-A1 | ANTI-RESORPTIVE BONE CEMENTS AND ALLOGENEIC, AUTOGRAFIC, AND XENOGRAFIC BONE GRAFTS | SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH (US) | 2000-08-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080286377-A1 | ANTI-RESORPTIVE BONE CEMENTS AND ALLOGENEIC, AUTOGRAFIC, AND XENOGRAFIC BONE GRAFTS | SOST, BMP6, BMP2 | TSHR 4385/4885ALDH1A1 2819/4885HCAR2 950/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.